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Mutations in presenilins are linked to familial autosomal dominant Alzheimer’s disease. In this issue of
Neuron, Xia et al. (2015) show that a disease-linked mutation leads to loss of g-secretase function, cognitive
decline, and neurodegeneration when knocked into the mouse genome.More than a century has passed since
Alois Alzheimer described a peculiar
pathology in the brain of a woman with a
progressive dementia (Alzheimer, 1907).
Since then, tens of thousands of papers
have been published on the topic of
Alzheimer’s disease (AD)—a PubMed
search for ‘‘Alzheimer’s disease’’ con-
ducted in February 2015 yielded 104,935
citations—yet the cause of the disease
remains unknown. Clues to the etiology
of AD have come from genetics and
from the identification of the proteins
that compose the characteristic lesions
of AD. In 1984, Glenner and Wong identi-
fied the b-amyloid peptide (Ab) as the
major protein component of the senile
plaques described by Alzheimer (Glenner
and Wong, 1984). Three years later, four
independent groups identified a gene on
human chromosome 21 that encodes
the Ab sequence as part of a larger pro-
tein, now called the amyloid precursor
protein (APP) (reviewed in Ashe and
Zahs, 2010). Subsequently, it was shown
that Ab is generated from APP by sequen-
tial cleavage by b- and g-secretases.
b-secretase first removes the majority of
the extracellular portion of the protein,
releasing sAPPb and leaving the APP
C-terminal fragment (CTF). Then g-secre-
tase first cuts the CTF within the mem-
brane at the ε cleavage site, producing
the APP intracellular domain (AICD) and
then cuts the remaining intracellular frag-
ment at a g site to generate Ab. Gamma
cleavage can produce Ab peptides of
various lengths, possibly via sequential
removal of amino acid residues from theC-terminal of Ab (Morishima-Kawashima,
2014).
Although most cases of Alzheimer’s
disease arise sporadically, some cases
(<10%) show an autosomal dominant
pattern of inheritance. All known muta-
tions causing familial autosomal dominant
Alzheimer’s disease (FAD) occur in the
APP gene or in genes encoding one of
the presenilin proteins, which form the
catalytic sub-unit of the g-secretase
enzyme complex. FAD-linked APP muta-
tions cause an over-all increase in levels
of Ab or increase the ratio of the more
aggregation-prone, 42-amino acid form
of Ab (Ab42) relative to the 40-amino
acid form (Ab40) (Alzforum, 2015). This is
important, because it has been shown
that the relative ratio of Ab42 to Ab40 is
a strong determinant of the toxicity of Ab
assemblies (Kuperstein et al., 2010).
FAD-linked presenilin mutations also con-
sistently lead to an increase in Ab42:Ab40
(reviewed in De Strooper, 2007). In addi-
tion, there is a wealth of experimental
evidence, derived from studies in vitro
and in C. elegans, showing that these
presenilin mutations result in (partial)
loss of g-secretase function (De Strooper,
2007; Shen and Kelleher, 2007). It has
been hypothesized that the mutations
increase Ab42:Ab40 by causing incom-
plete digestion of the Ab peptide at
the g site (De Strooper, 2007).
Based on the genetic findings, two
competing hypotheses have been put
forward to explain the etiology of AD.
The Amyloid Cascade Hypothesis posits
that AD is triggered by abnormal accu-Neuronmulation of toxic Ab species (Hardy and
Higgins, 1992). The Presenilin Hypothesis
posits that partial loss of presenilin func-
tion underlies memory impairment and
neurodegeneration in AD (Shen and Kel-
leher, 2007). Under the latter theory, a
change in the Ab42:40 ratio may arise
secondarily to loss of presenilin function,
but this is not the key pathogenic trigger
for AD. How APP mutations cause
FAD under the Presenilin Hypothesis is
not immediately obvious, although it has
been suggested that the Ab42 peptide
might itself partially inhibit presenilin
function (Shen and Kelleher, 2007).
The Amyloid Cascade and Presenilin
hypotheses lead to very different strate-
gies for developing Alzheimer’s therapeu-
tics. The Amyloid Cascade Hypothesis
would support interventions aimed at
promoting clearance of Ab (e.g., anti-Ab
immunotherapy) or reducing its gene-
ration (e.g., b- or g-secretase inhibitors).
The Presenilin Hypothesis would en-
courage intervention to restore presenilin
activity, perhaps even through activation
of g-secretase. Although g-secretase in-
hibitors are currently out of favor following
a disastrous Phase III trial, debate con-
tinues over whether they might provide
therapeutic benefits in AD (De Strooper,
2014). In this context, a critical question
is how FAD-linked mutations in preseni-
lins affect g-secretase function in vivo.
In this issue of Neuron, Shen, Kelleher,
and colleagues (Xia et al., 2015) used a
knockin (KI) strategy to assess the in vivo
effects of two FAD-linked mutations in
presenilin-1 (PS1), L435F and C410Y,85, March 4, 2015 ª2015 Elsevier Inc. 893
Figure 1. Summary of the Neurological Effects of the FAD-Linked
L435F Mutation in Presenilin-1
Effects of presenilin deletion (Saura et al., 2004) are shown in the fourth row for
comparison. ‘‘mt,’’ naturally occurring mutation in humans or L435F mutation
introduced into the genomic Psen1 locus in mice.
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shown virtually eliminate g-
secretase function in vitro
(Heilig et al., 2013). They first
showed that these FAD-
related mutations abolished
the function of PS1 in vivo,
thus inactivating gamma-
secretase. Gamma-secretase
products (Notch intracellular
domain and APP intracellular
domain) were absent from
the brains of mice homo-
zygous for the mutations
(KI/KI), while substrates of
g-secretase (APP- and N-
cadherin- C-terminal frag-
ments) accumulated, similar
to what is observed in the
brains of PS null mice. No Ab
was produced by extracts
from embryonic KI/KI brains
in an assay of de novo Ab
generation. Using extracts of
KI/wild-type (WT) brains, denovo generation of Ab was reduced to
50% of that by wild-type extracts, with
levels of Ab40 and Ab42 equally affected
by the mutations. Paradoxically, although
the mutations did not alter the ratio of
Ab42:Ab40 generated by g-secretase
activity, the ratio of the steady-state level
of Ab42 to Ab40 did increase. This sur-
prising finding suggests the intriguing
possibility that presenilin mutations could
somehow influence the aggregation and/
or clearance of Ab. KI/KI mice showed
the same perinatal lethality and neuro-
developmental abnormalities observed in
PS1 null mice (Shen et al., 1997).
Xia et al. (2015) then went on to assess
the neurological consequences of the
L435F mutation (Figure 1). Because they
had previously observed that loss of PS1
function results in a compensatory upre-
gulation of presenilin-2 (PS2), they stud-
ied synaptic and memory function in
KI/WT mice on a PS2 null background.
Compared to littermates with two WT
PS1 alleles, the KI/WTmice exhibited def-
icits in hippocampal-dependent memory
and in hippocampal synaptic plasticity.
The Shen lab had previously shown
that loss of presenilin function in the adult
mouse brain caused progressive cogni-
tive decline, neurodegeneration, and
gliosis, all characteristics of AD (Saura
et al., 2004). Because genetic ablation of894 Neuron 85, March 4, 2015 ª2015 Elseviepresenilins results in perinatal lethality,
they devised a clever strategy to study
the effects of loss of presenilin in the adult
brain. In a PS2 null background, mice with
floxed PS1 alleles were crossed with mice
expressing Cre-recombinase under the
control of the calcium-calmodulin kinase
II promoter. In such mice, PS1 levels
declined in forebrain neurons beginning
at 3 weeks of age. In the current study,
Xia et al. (2015) isolated the effects of
the mutant L435F-PS1 by using the
same strategy to eliminate expression of
wild-type PS1 in the adult forebrain, on a
PS2 null background. Compared to litter-
mates expressing either one or two wild-
type PS1 alleles, mice expressing one
copy of L435F-PS1 showed a decrease
in cortical volume, a decrease in neuron
number in the cortex, and an increase in
astrogliosis. These results show that, in
the absence of PS2, L435F-PS1 cannot
support aging neurons.
Like most good science, this study rai-
ses as many questions as it answers.
First, is g-secretase function necessary
to support aging neurons? If g-secretase
function is critical, which substrate is
involved—APP or one of the many other
targets of g-secretase (Wakabayashi and
De Strooper, 2008)? If the substrate is
APP, is the critical event the loss of Ab
or AICD acting as trophic factors or ther Inc.accumulation of toxic APP
CTF’s? Finally, is the neuro-
degeneration seen by Xia
et al. (2015) necessarily a
consequence of the loss of
g-secretase function or might
PSs have functions indepen-
dent of g-secretase (Waka-
bayashi and De Strooper,
2008)? FAD is not associated
with mutations in other g-sec-
retase subunits, suggesting
that it might not be the loss
of g-secretase function that
is responsible for the patho-
genicity of PS mutations.
We also must ask to what
degree the results of the ex-
periments of Xia et al. (2015)
can be extrapolated to the
human disease. In order to
see the neurodegenerative
phenotype resulting from
knocking in the L435F PS1
mutation, the authors elimi-nated all wild-type PS alleles (PS1 and
PS2). Human carriers of FAD-linked PS1
mutations have one intact copy of PS1 in
addition to two copies of PS2. However,
such ‘‘genetic exaggeration’’ is routinely
done in modeling human diseases in
mice; for example, APP transgenic mice
frequently overexpress several-fold hu-
man APP containing one or more FAD
mutations. It is possible that such genetic
exaggeration represents an acceleration
of phenomena that in humans result
from the accumulation of small insults
over years or decades, but this is hard to
validate in humans.
Based on their data, Xia et al. (2015)
provide a model in which PS1 mutations
that inhibit g-secretase function act via
two mechanisms, which then converge
to cause AD: (1) synaptic dysfunction
leads to neurodegeneration indepen-
dently of Ab; (2) Ab deposits contribute
to AD via an undefined mechanism. (We
would suggest that soluble Ab assem-
blies rather than amyloid plaques are
the pathogenic entities.) Further experi-
mentation is needed to test the validity
of this model, and to determine whether
both of these mechanisms are necessary
or whether either is sufficient to trigger
AD. However, it is not clear how such ex-
periments could be accomplished using
current animals models, which require
Neuron
Previewsgenetic exaggeration to recapitulate the
key features of AD.
Human clinical trials may provide a lab-
oratory to test theories about the etiology
of AD. Two large-scale prevention trials
are currently underway to test the effects
of anti-amyloid immunotherapy in people
with FAD. One trial will enroll subjects
with either APP or PS mutations, while
the second trial will focus on a large
Columbian kindred with a mutation in
PS1. If the trials succeed, they will provide
strong support for the Amyloid Cascade
Hypothesis. However, if they fail, what
can one conclude? Pharmacokinetic con-
siderations aside, the most likely explana-
tions are that: (1) the target (i.e., Ab) was
correct, but that the timing of intervention
and/or the antibody were wrong, or (2)
Ab was the wrong target. If the trials
fail to produce the expected results, thefindings in Xia et al. (2015) may provide
an early clue as to why.REFERENCES
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Circadian behavior in mammals is coordinated by neurons within the suprachiasmatic nucleus (SCN). In this
issue, Lee et al. (2015) and Mieda et al. (2015) applied state-of-the-art genetic tools to dissect the microcir-
cuits within the SCN generating circadian rhythmic behavior.One of the fundamental goals of neurosci-
ence is to link specific brain regions to
specific functions. While in many cases
this goal has proven elusive, an over-
whelming body of evidence shows that
the suprachiasmatic nuclei (SCN) of the
anterior hypothalamus are the site of
the master circadian pacemaker in
mammals. The SCN functions to synchro-
nize a network of circadian oscillations
throughout the body; the resulting circa-
dian rhythms have a profound impact on
our health and wellbeing. In addition to
the identification of the SCN as a key re-
gion regulating circadian activity, at thecellular level, we currently have a relatively
firm understanding of the transcriptional/
translational feedback loops that are
responsible for generation of these mo-
lecular oscillations. However, major gaps
remain in understanding circadian regula-
tion at the intermediate level of analysis,
including the roles of specific cell-types
within the SCN. Two exciting back-to-
back studies in this issue have applied
state-of-the-art genetics tools to analyze
the SCN and make headway in under-
standing its circuitry and its role in circa-
dian rhythmic behavior (Lee et al., 2015;
Mieda et al., 2015).Some of the challenges in studying the
function of the SCN and its subpopula-
tions lie in its structure. Anatomical
studies generally support the division of
the SCN into at least two subdivisions
including a dorsal (shell) region and a
ventral (core) region (Figure 1; top). At
the cellular/synaptic however, the SCN
can be likened to a tightly packed ball,
composed of GABAergic neurons whose
synaptic connections form more of a
plexus rather than an ordered structure
like the hippocampus, cortex, or cere-
bellum. Furthermore, an influential study
using fully isolated SCN neurons found85, March 4, 2015 ª2015 Elsevier Inc. 895
